JP Morgan Chase’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $120M | Buy |
1,553,644
+129,655
| +9% | +$12.6M | 0.01% | 910 |
|
|
2025
Q4 | $152M | Buy |
1,423,989
+235,920
| +20% | +$25M | 0.01% | 767 |
|
|
2025
Q3 | $120M | Buy |
1,188,069
+404,510
| +52% | +$37.6M | 0.01% | 902 |
|
|
2025
Q2 | $49.5M | Buy |
783,559
+639,919
| +446% | +$39.2M | ﹤0.01% | 1335 |
|
|
2025
Q1 | $7.61M | Sell |
143,640
-120,945
| -46% | -$6.71M | ﹤0.01% | 2783 |
|
|
2024
Q4 | $14.8M | Buy |
264,585
+182,993
| +224% | +$10.1M | ﹤0.01% | 2322 |
|
|
2024
Q3 | $4.27M | Sell |
81,592
-58,554
| -42% | -$2.81M | ﹤0.01% | 3328 |
|
|
2024
Q2 | $5.75M | Buy |
140,146
+85,642
| +157% | +$3.42M | ﹤0.01% | 2932 |
|
|
2024
Q1 | $2.36M | Sell |
54,504
-23,095
| -30% | -$1.01M | ﹤0.01% | 3716 |
|
|
2023
Q4 | $3.57M | Buy |
77,599
+5,188
| +7% | +$164K | ﹤0.01% | 3389 |
|
|
2023
Q3 | $1.66M | Buy |
72,411
+2,823
| +4% | +$63.2K | ﹤0.01% | 3692 |
|
|
2023
Q2 | $1.15M | Buy |
69,588
+47,303
| +212% | +$854K | ﹤0.01% | 3949 |
|
|
2023
Q1 | $398K | Buy |
22,285
+2,644
| +13% | +$66.4K | ﹤0.01% | 4638 |
|
|
2022
Q4 | $572K | Buy |
19,641
+17,430
| +788% | +$448K | ﹤0.01% | 4427 |
|
|
2022
Q3 | $54K | Buy |
2,211
+1,770
| +401% | +$32.9K | ﹤0.01% | 5520 |
|
|
2022
Q2 | $2K | Sell |
441
-26,540
| -98% | -$145K | ﹤0.01% | 6295 |
|
|
2022
Q1 | $312K | Buy |
26,981
+4,701
| +21% | +$41.3K | ﹤0.01% | 4960 |
|
|
2021
Q4 | $223K | Sell |
22,280
-221
| -1% | -$2.48K | ﹤0.01% | 5291 |
|
|
2021
Q3 | $293K | Buy |
22,501
+332
| +1% | +$5.07K | ﹤0.01% | 5031 |
|
|
2021
Q2 | $434K | Sell |
22,169
-57,656
| -72% | -$1.2M | ﹤0.01% | 4780 |
|
|
2021
Q1 | $1.7M | Sell |
79,825
-8,435
| -10% | -$245K | ﹤0.01% | 3837 |
|
|
2020
Q4 | $2.62M | Sell |
88,260
-2,594
| -3% | -$65.9K | ﹤0.01% | 3287 |
|
|
2020
Q3 | $2.02M | Sell |
90,854
-5,017
| -5% | -$115K | ﹤0.01% | 3230 |
|
|
2020
Q2 | $2.14M | Sell |
95,871
-8,145
| -8% | -$159K | ﹤0.01% | 3060 |
|
|
2020
Q1 | $1.58M | Sell |
104,016
-16,867
| -14% | -$302K | ﹤0.01% | 3116 |
|
|
2019
Q4 | $2.78M | Sell |
120,883
-5,661
| -4% | -$126K | ﹤0.01% | 3132 |
|
|
2019
Q3 | $2.73M | Sell |
126,544
-291
| -0.2% | -$6.24K | ﹤0.01% | 3198 |
|
|
2019
Q2 | $2.75M | Buy |
126,835
+3,057
| +2% | +$77.2K | ﹤0.01% | 3156 |
|
|
2019
Q1 | $3.39M | Sell |
123,778
-321
| -0.3% | -$9.22K | ﹤0.01% | 2914 |
|
|
2018
Q4 | $3.34M | Sell |
124,099
-5,255
| -4% | -$145K | ﹤0.01% | 2882 |
|
|
2018
Q3 | $3.77M | Sell |
129,354
-29,720
| -19% | -$939K | ﹤0.01% | 2970 |
|
|
2018
Q2 | $4.97M | Buy |
159,074
+1,621
| +1% | +$44.3K | ﹤0.01% | 2686 |
|
|
2018
Q1 | $3.13M | Buy |
157,453
+39,476
| +33% | +$1.05M | ﹤0.01% | 2951 |
|
|
2017
Q4 | $3.43M | Buy |
+117,977
| New | +$3.12M | ﹤0.01% | 2973 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
JP Morgan Chase's RYTM Position: Q1 2026 in Review
JP Morgan Chase increased its Rhythm Pharmaceuticals (RYTM) stake by 9.1% in Q1 2026, buying an estimated $12.6M and bringing the position to 1,553,644 shares worth $120M. The position accounts for 0.01% of the portfolio, ranked #910.
JP Morgan Chase first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $152M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- JP Morgan Chase held 1,553,644 shares of Rhythm Pharmaceuticals worth $120M as of Q1 2026.
- JP Morgan Chase bought 129,655 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $12.6M.
- Rhythm Pharmaceuticals made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #910 holding.
- JP Morgan Chase first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- JP Morgan Chase's Rhythm Pharmaceuticals position peaked at $152M in Q4 2025.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.